Isopropamide

Summary

Isopropamide (CHEMBL1201232) is an approved small molecule (ATC A03AB09); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A03AB09
• Indications: 1 condition
• Chemistry: 353.5 Da · C23H33N2O+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201232
Name	Isopropamide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3775
ATC	A03AB09
Molecular formula	C23H33N2O+
Molecular weight	353.5
InChIKey	JTPUMZTWMWIVPA-UHFFFAOYSA-O

SMILES: CC(C)[N+](C)(CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)C(C)C

IUPAC name: (4-amino-4-oxo-3,3-diphenylbutyl)-methyl-di(propan-2-yl)azanium

Also known as: Isopropamide, Isopropamide cation, Isopropamide ion, SID11112197, SID144203913, ISOPROPAMIDE, SID170465291, ISOPROPAMIDE-IODIDE, ISOPROPAMIDE IODIDE, isopropamide

Parent form; salt/anhydrous children: CHEMBL1200347

Patent coverage: 1,206 distinct patent families (3,737 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Prelamin-A/C, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M3, Cytochrome P450 2D6.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 8 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM3	8.25	AC50	5.6	nM	CHEMBL_ACT_25136861
CHRM2	8	AC50	10	nM	CHEMBL_ACT_25213905
CHRM2	7.92	AC50	12	nM	CHEMBL_ACT_25195312
CHRM1	7.89	AC50	13	nM	CHEMBL_ACT_25135633
KCNH2	5.48	AC50	3300	nM	CHEMBL_ACT_25118113
LMNA	5.45	Potency	3548	nM	CHEMBL_ACT_3645432
CYP2D6	5.4	Potency	3981	nM	CHEMBL_ACT_4973902
CYP2D6	5.4	AC50	3981	nM	CHEMBL_ACT_5987297

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).